MyAlcon | International

This site is available in English. Select below for other locations.

Valeda™ PBM is the first FDA-authorized and CE marked treatment for dry AMD to improve and maintain vision for up to 2 years^1,8*

*Dry AMD eyes with: 3 medium drusen, or 1 large drusen, or non-central involving GA; and with BCVA between 20/32 - 20/70. (i.e., early and intermediate dry AMD, and a sub-set of late dry AMD).

Valeda™ PBM LIGHTSITE III clinical trial met the predetermined primary efficacy endpoint at Month 21^2†

84% of Valeda™ PBM–treated patients improved or maintained vision at ~2 years compared to baseline^3,4†

More than 60% of Valeda™ PBM–treated patients experienced ≥1-line vision improvement at about 2 years compared to baseline^3,4†

† n=98 subjects and 145 eyes

Assessing the Efficacy and Safety of Valeda™ PBM

LIGHTSITE III Pivotal Trial Design

Study design

LIGHTSITE III evaluated the efficacy and safety of Valeda™ PBM in a 24-month, double-masked, sham-controlled, parallel design, prospective, randomized, multi-center trial.^4,5

Study population

98 patients (145 eyes) aged ≥50 years with an ETDRS BCVA letter score between 50 and 75 and a diagnosis of dry AMD, defined by the presence of drusen and/or nonfoveal center GA, were randomized at a 2:1 ratio into 2 treatment groups.⁴

Endpoints

Primary efficacy endpoint:
Mean BCVA change from baseline to Month 13 or Month 21.
Primary safety endpoint:
Mean change from baseline to Month 13 or Month 24.⁴

Valeda™ PBM Improved and Maintained Vision

84% of Valeda™ PBM–treated patients maintained or improved vision at about 2 years compared to baseline.^3,4†

More than 60% of Valeda™ PBM–treated patients experienced ≥1‑line vision improvement at about 2 years compared to baseline.^3,4†

† n=98 subjects and 145 eyes

No phototoxicity or serious adverse events related

to Valeda™ PBM^2,4

Consistent safety in multiple clinical trials

0 reports of phototoxicity in 3

LIGHTSITE trials²

of patients did not >97% report eye pain⁴

Non-Invasive Treatment.

Dilation free. Anesthesia free. Speculum free. Injection free.⁴

Treatment regimen consists of 54 applications administrated in 6 courses over 2 years

¶ 3-5 weeks

‡ For 2 years

Valeda™ PBM Uses the Power of Light

Valeda™ PBM applies 3 science-backed wavelengths to upregulate cellular energy production^6,7

590 nm

Increases nitric oxide synthesis and vasodilation which can improve local oxygenation and nutrient delivery⁶

660 nm

Promotes O₂ binding (Cu_B), stimulates metabolic activity (ATP), and inhibits inflammation and cell death⁷

850 nm

Drives electron transfer (Cu_A), stimulates metabolic activity (ATP), and inhibits inflammation and cell death⁷

Valeda™ PBM’s unique mechanism of action works to restore cellular energy production and improve retinal cellular health⁵

The retina is rich in mitochondria, and mitochondrial dysfunction is a known cause of vision loss in dry AMD.

Cytochrome c oxidase (CcO) is a key photoacceptor in the mitochondrial electron transport chain.

Valeda™ PBM wavelengths activate CcO, enhancing electron transport and mitochondrial adenosine triphosphate (ATP) production, the cell’s major source of energy.

No More Watch and Wait. Treat With Valeda™ PBM

First and only Valeda™ PBM is the first FDA‑authorized and CE‑marked treatment for dry AMD to improve and maintain vision for up to two years.^1,8*

Improve and maintain vision
84% of Valeda™ PBM–treated patients improved or maintained vision at ~2 years compared to baseline.^3,4*

A noninvasive treatment Dilation‑free, speculum‑free, anesthesia‑free, and injection‑free.⁴

*n=98 subjects and 145 eyes.

Alcon medical device(s) comply with the current legislation for medical devices. Please refer to relevant product instructions for use for complete list of indications, contraindications and warnings.

References:
1. Valeda US Instructions for Use.
2. Valeda Clinical Study Report. 2023. [REF-28073]
3. Valeda US LIGHTSITE III Exhibit Data. [REF-28187]
4. Valeda US User Manual 2025
5. Boyer D, Hu A, Warrow D, et al. 13-Month eﬃcacy and safety evaluation of multiwavelength photobiomodulation in nonexudative (dry) age-related macular degeneration using the Lumithera Valeda Light Delivery System. Retina. 2024;44(3):487-497. doi:10.1097/IAE.0000000000003980
6. Ball KA, Castello PR, Poyton RO. Low intensity light stimulates nitrite-dependent nitric oxide synthesis but not oxygen consumption by cytochrome c oxidase: Implications for phototherapy. J Photochem Photobiol B. 2011;102(3):182-191.
7. Wong-Riley MT, Liang HL, Eells JT, et al. Photobiomodulation directly benefits primary neurons functionally inactivated by toxins: role of cytochrome c oxidase. J Biol Chem. 2005;280(6):4761-4771.Valeda US Instructions for Use.
8. Alcon Data on File, 2025. REF-27576

Valeda™ PBM is the first FDA-authorized and CE marked treatment for dry AMD to improve and maintain vision for up to 2 years1,8*

Valeda™ PBM LIGHTSITE III clinical trial met the predetermined primary efficacy endpoint at Month 212†

84% of Valeda™ PBM–treated patients improved or maintained vision at ~2 years compared to baseline3,4†

More than 60% of Valeda™ PBM–treated patients experienced ≥1-line vision improvement at about 2 years compared to baseline3,4†

Assessing the Efficacy and Safety of Valeda™ PBM

Valeda™ PBM Improved and Maintained Vision

84% of Valeda™ PBM–treated patients maintained or improved vision at about 2 years compared to baseline.3,4†

More than 60% of Valeda™ PBM–treated patients experienced ≥1‑line vision improvement at about 2 years compared to baseline.3,4†